Table 2.
Mean change (95% confidence interval) and results of pairwise comparisons for four treatments at month 10 and month 16
| Outcome measure | Optimised acute treatment | Optimised acute treatment plus behavioural migraine management | |||
|---|---|---|---|---|---|
| Plus placebo (n=55) | Plus β blocker (n=53) | Plus placebo (n=55) | Plus β blocker (n=69) | ||
| Month 10 | |||||
| Migraines/30 days | −2.1 (−1.9 to −2.2) | −2.1 (−1.9 to −2.2) | −2.2 (−2.0 to −2.4) | −3.3* (−3.2 to −3.5) | |
| Migraine days/30 days | −3.3 (−3.0 to −3.6) | −3.9 (−3.5 to −4.2) | −3.3 (−2.9 to −3.7) | −5.4* (−5.2 to −5.6) | |
| Migraine specific quality of life scores | −7.1 (−6.3 to −7.8) | −7.1 (−6.6 to −7.7) | −8.6* (−8.2 to −8.9) | −13.0* (−12.5 to −13.5) | |
| Month 16 | |||||
| Migraines/30 days | −2.5 (−2.3 to −2.6) | −2.5 (−2.2 to −2.8) | −2.7 (−2.5 to −2.9) | −3.8* (−3.5 to −4.0) | |
| Migraine days/30 days | −3.9 (−3.5 to −4.3) | −4.5 (−4.0 to −5.1) | −4.1 (−3.8 to −4.5) | −6.1* (−5.6 to −6.6) | |
| Migraine specific quality of life scores | −8.8 (−8.1 to −9.5) | −8.5 (−7.6 to −9.4) | −9.6 (−9.0 to −10.3) | −15.2* (−14.4 to −16.0) | |
*Differ significantly from other three treatments with Bonferroni adjustment (P<0.0083).